FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

P	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average h	ourdon							

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				0	Secu	30(11)	or trie	investment C	ompany Act	01 1940							
1. Name and Address of Reporting Person* Naeve Gregory S.				<u>B</u>	2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC BLCM							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
					[DEGIT]							X Officer below)	(give title		Other (s below)	pecify	
(Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2019							Chief Business Officer					
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street) HOUST(ON T	X	77030								Line	X Form f	,	•	orting Persor		
(City)	(S	tate)	(Zip)	-								Persor		e ulali	Опе керог	urig	
		Tab	le I - Non-Do	erivativ	e Se	curities	s Ac	guired, Di	sposed o	of, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D:				е	Execution Date,			Code (Instr. 5)				5. Amou Securitie Beneficia Owned F	es Fo ally (D) Following (I)	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	on(s)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		oer ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$3.35	02/01/2019		A		75,000		(1)	01/31/2029	Common Stock	75,000	\$0	75,000)	D		

${\bf Explanation\ of\ Responses:}$

1. 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.

Remarks:

/s/ Rosemary Y. Williams, Attorney-in-Fact 02/05/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.